Overview

The POUR (Postoperative Urinary Retention) Study

Status:
Not yet recruiting

Trial end date:
2022-09-01

Target enrollment:

Participant gender:

Summary

The primary aim of this study will be to compare the rate of postoperative urinary retention between patients receiving Sugammadex and those receiving traditional reversal agents

Phase:

Phase 3

Details

Lead Sponsor:

Todd Heniford

Collaborator:

Merck Sharp & Dohme Corp.